IngentaConnect IL-13: A Promising Therapeutic Target for Bronchial Asthma

Authors: Izuhara, K.¹; Arima, K.¹; Kanaji, S.¹; Ohta, S.¹; Kanaji, T.¹

Source: Current Medicinal Chemistry, Volume 13, Number 19, August 2006 , pp. 2291-2298(8)

Publisher: Bentham Science Publishers

Abstract:

The incidence of allergic diseases has dramatically increased in recent decades, especially in urban and industrialized areas. It is important socially as well as medically to establish more useful strategies to overcome allergic disorders. Bronchial asthma is a complex disease characterized by airway inflammation involving a Th2-cytokine, interleukin (IL)-13. A substantial body of evidence has accumulated pointing to the pivotal role of IL-13 in the pathogenesis of bronchial asthma, based on mainly analyses of mouse models. In addition to such analyses, the high expression of IL-13 in lesions and genetic association of several genes coding IL-13 signaling molecules with bronchial asthma have raised the possibility that IL-13 plays a pivotal role in the onset or exacerbation of human bronchial asthma. Therefore, IL-13 and its signal pathway are thought to be promising targets to develop a therapeutic agent for bronchial asthma. In this article, we describe how IL-13 is involved in the pathogenesis of bronchial asthma and then how therapeutic agents to block IL-13 signals are developed for bronchial asthma.

Keywords: Allergic disease; bronchial asthma; interleukin-13; interleukin-4; the interleukin-13 receptor; signal pathway; agent; therapeutic target

Document Type: Research article

DOI: 10.2174/092986706777935140

Affiliations: 1: Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, 5-1-1, Nabeshima, Saga, 849-8501, Japan.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy